Skip to content
Open access

Hemostatic Profiling of Generic Factor Xa Inhibitors Using ROTEM® Viscoelastometry and Multimodal Coagulation Assays: A Real-World Study in a Tunisian Cohort

Jul 2026 · F1000Research · Vol 15, pp. 1184 · 0 citations · 24 references

TL;DR

Generic factor Xa inhibitors show hemostatic profiles mirroring those of brand-name versions, making it a practical bedside surrogate in urgent settings, making it a practical bedside surrogate in urgent settings.

Abstract

Background The emergence of generic direct factor Xa inhibitors like apixaban and rivaroxaban has significantly increased the global availability of essential anticoagulants in developing nations. However, we still lack a detailed understanding of how these generic versions behave in real-world clinical practice. This research offers an initial multimodal evaluation, within a Tunisian population, integrating conventional coagulation tests with specific anti-Xa activity and rotational thromboelastometry. Methods We conducted a prospective cross-sectional study at Sahloul University Hospital (Sousse, Tunisia) including 33 patients (mean age 71.3 ± 11.7 years) receiving generic apixaban (n = 25) or rivaroxaban (n = 8) for ≥1 month. Sixty-six paired blood samples were collected at trough (30 min before the next dose) and peak (2–3 h after intake). Standard coagulation tests (PT, aPTT, fibrinogen), calibrated chromogenic anti-Xa activity, and ROTEM®sigma assays were performed. Results Rivaroxaban produced consistent PT prolongation at trough (87.5%) and peak (100%), while apixaban exerted a milder, concentration-dependent effect (45.5% at trough; 73.9% at peak). PT correlated inversely with anti-Xa activity for both agents (apixaban: r = −0.79 at peak; rivaroxaban: r = −0.84 at peak). aPTT and fibrinogen were not significantly affected. Among ROTEM parameters, EXTEM clotting time (CT) was the sole viscoelastic parameter significantly correlated with anti-Xa activity: rivaroxaban r = 0.88 (p = 0.004) at trough and r = 0.87 (p = 0.012) at peak; apixaban ρ = 0.54 (p = 0.021) at trough and ρ = 0.69 (p < 0.001) at peak. INTEM CT showed no significant correlation for either agent. Clot firmness, formation time, and maximum lysis were unaffected by either agent. Conclusion Generic factor Xa inhibitors show hemostatic profiles mirroring those of brand-name versions. EXTEM CT emerged as the ROTEM® parameter most closely tied to anticoagulant intensity, making it a practical bedside surrogate in urgent settings.

Read PDF

Similar papers

Open access Aug 2026

Real-World Assessment of Direct Oral Factor Xa Inhibitors: Dosing Appropriateness, Drug Exposure, and Inter-Platform Comparability of Chromogenic Anti-Xa Assays

Real-world outpatient DOAC concentrations demonstrated substantial variability and frequent off-label underdosing; these findings may nonetheless support individualized interpretation of outpatient spot sample DOAC concentrations in selected clinical settings.

Yoonjung Kim, Sojin Lee, Yongjung Park et al. · 0 citations
Open access Aug 2026

Heparin-calibrated anti-factor Xa activity as a surrogate marker for direct oral anticoagulant levels in acute stroke care: a large observational single-center study

Defined anti-Xa cut-offs are highly specific and sensitive and enable rapid and standardized assessment of anticoagulant activity in this cohort and Heparin-calibrated anti-Xa activity is a reliable surrogate marker for clinically relevant DOAC levels.

M. Büchsel, Katharina Lisko, H. Gölz et al. · 0 citations
Clinical trial Open access Jan 2026

Clinical Validation of a Point-of-Care Whole Blood Coagulometer in Patients on Factor Xa Inhibitors

ClotChek clotting times showed good sensitivity and specificity to identify meaningful anticoagulation among patients taking apixaban or rivaroxaban, and could aid physicians at the point of care in making therapeutic decisions in patients with adverse events associated with oral factor Xa inhibitors.

S. Bakhru, Jean M. Connors, Robert P. Giugliano et al. · 0 citations

Thrombosis and Haemostasis Clinical Validation of a Point-of-Care Whole Blood Coagulometer in Patients on Factor Xa Inhibitors

ClotChek clotting times showed good sensitivity and specificity to identify meaningful anticoagulation among patients taking apixaban or rivaroxaban, and could aid physicians at the point of care in making therapeutic decisions in patients with adverse events associated with oral factor Xa inhibitors.

S. Bakhru, Jean M. Connors, Robert P. Giugliano et al. · 0 citations
Review Sep 2026

Preanalytical stability of aPTT and anti-Xa levels for therapeutic unfractionated heparin monitoring: a systematic review and critical appraisal using CRESS criteria

Future stability studies should comply with CRESS recommendations, use standardized acceptability criteria, and incorporate clinically relevant outcomes, including patient reclassification, to establish evidence-based recommendations for UFH monitoring.

Annabelle Dupont, Isabelle Gouin-Thibault, Thomas Lecompte et al. · 0 citations
Sep 2026

Impact of a 15-minute incubation on citrated TEG (thromboelastography) results in adult surgical patients-a prospective observational study.

A 15-minute incubation significantly shortens CK-R/CKH-R and marginally decreases CK-MA, potentially normalizing hyper- or hypocoagulable readings, and strict adherence to the manufacturer's incubation protocol is recommended except in emergencies.

Hong Hong, A. Hasenzahl, Mohamed T. Abdelfattah et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.